Manuel Barreiro‐de Acosta
YOU?
Author Swipe
View article: Indoor radon concentration and risk and severity of inflammatory bowel diseases: a case–control study
Indoor radon concentration and risk and severity of inflammatory bowel diseases: a case–control study Open
Background: Inflammatory bowel disease (IBD) develops from a dysregulated immune response influenced by environmental exposures. Radon, a radioactive gas, has known biological effects, but its role in IBD remains unexplored. Objectives: To…
View article: Patient-reported outcome measures poorly correlate with objective inflammatory bowel disease activity measures: a systematic review
Patient-reported outcome measures poorly correlate with objective inflammatory bowel disease activity measures: a systematic review Open
Background and Aims We investigated the correlations between patient-reported outcome measures (PROMs) and other measures of inflammatory bowel disease (IBD) activity. Methods A systematic literature review was performed up to June 2022. S…
View article: Exploration of JAK/STAT pathway activation in ulcerative colitis reveals sex-dependent activation of JAK2/STAT3 in the inflammatory response
Exploration of JAK/STAT pathway activation in ulcerative colitis reveals sex-dependent activation of JAK2/STAT3 in the inflammatory response Open
Introduction Ulcerative colitis (UC) is characterized by aberrant immune responses involving multiple inflammatory pathways, including JAK/STAT signaling. However, the specific roles and interactions of individual components within this pa…
View article: Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics
Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics Open
Introduction Dysbiosis is a key mechanism in inflammatory bowel disease (IBD) pathophysiology. Previous microbiota studies in IBD generally have involved patients treated with immunosuppressive agents, which can affect the results. We aime…
View article: Prevalence of Undiagnosed Inflammatory Bowel Disease in Spondyloarthritis Patients
Prevalence of Undiagnosed Inflammatory Bowel Disease in Spondyloarthritis Patients Open
Background/Objectives: The prevalence of inflammatory bowel disease (IBD) in spondyloarthritis (SpA) patients is unknown. Our objective was to assess the prevalence of undiagnosed IBD in SpA patients, including those with axial spondylarth…
View article: ABS0697 DIFFERENT PREVALENCE OF INTESTINAL INFLAMMATION IN RADIOGRAPHIC AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. DATA FROM THE EISER STUDY
ABS0697 DIFFERENT PREVALENCE OF INTESTINAL INFLAMMATION IN RADIOGRAPHIC AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. DATA FROM THE EISER STUDY Open
View article: Influence of Familial Inflammatory Bowel Disease History on the Use of Immunosuppressants, Biological Agents and Surgery in Patients with Pediatric-Onset of the Disease in the Era of Biological Therapies. Results from the ENEIDA Registry
Influence of Familial Inflammatory Bowel Disease History on the Use of Immunosuppressants, Biological Agents and Surgery in Patients with Pediatric-Onset of the Disease in the Era of Biological Therapies. Results from the ENEIDA Registry Open
Background: Pediatric-onset familial inflammatory bowel disease (IBD) may differ from sporadic pediatric-onset IBD in its genetic and environmental background and may have distinct clinical and therapeutic implications. Objective: To evalu…
View article: Fidaxomicin for <i>Clostridioides difficile</i> infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study
Fidaxomicin for <i>Clostridioides difficile</i> infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study Open
Background and aims Inflammatory bowel disease (IBD) patients with Clostridioides difficile infection (CDI) are at increased risk of adverse outcomes. Data on fidaxomicin use in IBD remain scarce. We assessed the effectiveness and safety o…
View article: Inter‐Rater Disagreements in Applying the Montreal Classification for Crohn's Disease: The Five‐Nations Survey Study
Inter‐Rater Disagreements in Applying the Montreal Classification for Crohn's Disease: The Five‐Nations Survey Study Open
Background The Montreal classification has been widely used in Crohn's disease since 2005 to categorize patients by the age of onset (A), disease location (L), behavior (B), and upper gastrointestinal tract and perianal involvement. With e…
View article: Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU Open
Background and objectives Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment versus thos…
View article: Documento de posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de la telemedicina en la enfermedad inflamatoria intestinal
Documento de posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de la telemedicina en la enfermedad inflamatoria intestinal Open
Inflammatory Bowel Disease (IBD) is a chronic digestive condition that requires continuous monitoring by healthcare professionals to determine appropriate therapy and manage short- and long-term complications. Telemedicine has become an es…
View article: Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective Open
Background Mucosal healing (MH) is an established treatment goal in inflammatory bowel disease (IBD). However, various definitions of MH exist. We aimed to identify how MH is defined in randomized controlled trials (RCTs) in ulcerative col…
View article: Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU
Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU Open
Background Telemonitoring for inflammatory bowel disease (IBD) has not consistently demonstrated superiority over standard care; however, noninferiority may be an acceptable outcome if remote care proves to be more efficient. Objective Thi…
View article: Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial
Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial Open
Introduction: Identifying novel treatment strategies for patients with ulcerative colitis (UC) and at risk of relapse is critical. The objective of this study was to assess the efficacy of beclomethasone dipropionate (BDP) in lowering feca…
View article: Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta‐analysis of randomized controlled trials
Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta‐analysis of randomized controlled trials Open
Background and objective Probiotics show promise in inflammatory bowel disease (IBD), yet knowledge gaps persist. We performed an overview of systematic reviews and an updated metanalysis of randomized controlled trials (RCT) assessing the…
View article: Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study
Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study Open
View article: Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Society of Digestive Endoscopy (SEED)
Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Society of Digestive Endoscopy (SEED) Open
Obesity is a multifactorial, chronic, progressive and recurrent disease considered a public health issue worldwide and an important determinant of disability and death. In Spain, its current prevalence in the adult population is about 24% …
View article: Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn’s disease: a case-control study
Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn’s disease: a case-control study Open
View article: Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU (Preprint)
Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU (Preprint) Open
BACKGROUND Telemonitoring for inflammatory bowel disease (IBD) has not consistently demonstrated superiority over standard care; however, noninferiority may be an acceptable outcome if remote care proves to be more efficient. OBJECTIVE …
View article: Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA Open
Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients fr…
View article: Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis Open
The treatment of inflammatory bowel disease has undergone a significant transformation following the introduction of biologic drugs. Thanks to these drugs, treatment goals have evolved from clinical response and remission to more ambitious…
View article: Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus Open
Background and Aims Pragmatic studies designed to test interventions in everyday clinical settings can successfully complement the evidence from registration and explanatory clinical trials. The European consensus project PRACTICE-IBD was …
View article: Influencing factors on the persistence of infliximab and adalimumab treatment in Crohn's disease
Influencing factors on the persistence of infliximab and adalimumab treatment in Crohn's disease Open
Aim The aim of the study was to define and compare persistence of infliximab and adalimumab according to the treatment line. The secondary objectives were to identify factors that influence persistence. Methods We performed an observationa…
View article: Recomendaciones sobre el manejo de la obesidad grave en pacientes con enfermedad inflamatoria intestinal del Grupo Español de Trabajo en Enfermedad Inflamatoria Intestinal (GETECCU), Sociedad Española de Obesidad (SEEDO), Asociación Española de Cirugía (AEC) y Sociedad Española de Endoscopia Digestiva (SEED)
Recomendaciones sobre el manejo de la obesidad grave en pacientes con enfermedad inflamatoria intestinal del Grupo Español de Trabajo en Enfermedad Inflamatoria Intestinal (GETECCU), Sociedad Española de Obesidad (SEEDO), Asociación Española de Cirugía (AEC) y Sociedad Española de Endoscopia Digestiva (SEED) Open
Obesity is a multifactorial, chronic, progressive and recurrent disease considered a public health issue worldwide and an important determinant of disability and death. In Spain, its current prevalence in the adult population is about 24% …
View article: Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study
Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study Open
View article: Documento de posicionamiento. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre sexualidad y enfermedad inflamatoria intestinal
Documento de posicionamiento. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre sexualidad y enfermedad inflamatoria intestinal Open
It is widely acknowledged that inflammatory bowel disease (IBD) is associated with a high prevalence of sexual dysfunction (SD). However, there is a notable paucity of specific literature in this field. This lack of information impacts var…
View article: Environmental Exposure to Trace Elements and Heavy Metals Preceding the Clinical Onset of Inflammatory Bowel Disease
Environmental Exposure to Trace Elements and Heavy Metals Preceding the Clinical Onset of Inflammatory Bowel Disease Open
Background The immune dysregulation underlying inflammatory bowel disease (IBD) can start years before the diagnosis, but the role of triggering factors and environmental exposures during this period is still uncertain. Methods This single…
View article: DOP03 Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey on processes and outcomes
DOP03 Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey on processes and outcomes Open
Background The European Crohn’s and Colitis Organisation (ECCO) Position Paper on Quality-of-Care (QoC) proposed essential standards on process and outcomes for units that manage patients with inflammatory bowel disease (IBD). The E-QUALIT…
View article: P987 Impact of Crohn’s Disease Location on Biologic Therapy Persistence and the Risk of Intestinal Surgery: Insights from the ENEIDA Registry (the DISCOLOC Study)
P987 Impact of Crohn’s Disease Location on Biologic Therapy Persistence and the Risk of Intestinal Surgery: Insights from the ENEIDA Registry (the DISCOLOC Study) Open
Background Crohn's disease (CD) presents differences in genetics, inflammatory components, and microbiota depending on its location. Therapy efficacy may be linked to disease location, but existing research has yielded conflicting results.…
View article: Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU
Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU Open
Background: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders. Objective: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders. Design: …